Astellas and Ambrx initiate collaboration for discovery and development of antibody drug conjugates for oncology

AstellasAstellas Pharma Inc. (Tokyo: 4503, "Astellas") entered into a collaboration with Ambrx Inc. ("Ambrx") for the discovery and development of novel antibody drug conjugates ("ADCs"). ADCs allow for the targeted delivery of drugs to the target tissue. Ambrx creates optimized ADCs using its site-specific conjugation technology along with proprietary linkers and payloads. In the preclinical setting, Ambrx ADCs have demonstrated high potency and a wider therapeutic index than ADCs created using conventional non-specific conjugation.

Ambrx will receive an upfront payment of $15 million from Astellas, as well as up to $285 million in potential near and long-term research, development, regulatory and sales-based milestones for an undisclosed number of targets for ADCs in oncology. A portion of these milestones, as well as royalties on any net sales, will be contingent on eventual successful commercialization of products developed as a result of this partnership. Astellas will receive worldwide rights to develop and commercialize ADCs for oncology. Additional terms of the collaboration are not disclosed at this time.

"Agensys, Inc., an affiliate of Astellas which specializes in therapeutic antibody research and development in cancer, has significant experience with ADCs as oncology therapeutics and is looking to further expand its capabilities in this area. Ambrx offers a novel approach to allow creation of site-specific and highly stable conjugations that have the potential to further optimize drug delivery to tumor cells." said David Stover, Ph.D., Senior Vice President and Agensys Site Head.

Added Lawson Macartney, chief executive officer of Ambrx, "We recognize Astellas as a leader in the development of innovative therapeutics for oncology and are proud to initiate this collaboration. We look forward to developing these therapeutics while also advancing our broad pipeline of partnered and wholly owned therapeutic candidates with best-in-class conjugation."

About Ambrx
Ambrx Inc. is a clinical stage biopharmaceutical company using an expanded genetic code to create best-in-class bio therapeutics, including antibody drug conjugates and proteins with improved pharmacologic properties. The company is developing ARX201, a long-acting growth hormone that has successfully completed Phase 2b clinical trials. Ambrx has collaborations to discover and develop products incorporating Ambrx technology with Bristol-Myers Squibb, Eli Lilly and Company and several undisclosed companies. Ambrx is advancing a robust portfolio of product candidates that are optimized for efficacy, safety and ease of use in multiple therapeutic areas.

About Astellas
Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. Astellas has approximately 17,000 employees worldwide. The organization is committed to becoming a global category leader in Urology, Immunology (including Transplantation) and Infectious Diseases, Oncology, Neuroscience and DM Complications and Kidney Diseases.

Most Popular Now

Sustained cellular immune dysregulation in individ…

COVID-19, which has killed 1.7 million people worldwide, does not follow a uniform path. Many infected patients remain asymptomatic or have mild symptoms. Others, espe...

New virtual screening strategy identifies existing…

A novel computational drug screening strategy combined with lab experiments suggest that pralatrexate, a chemotherapy medication originally developed to treat lymphoma, c...

Pfizer and BioNTech to supply the U.S. with 100 mi…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a second agreement with the U.S. government to supply an additional 100 million doses of the compan...

European Commission authorizes COVID-19 vaccine Mo…

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the European Commission has granted a cond...

An in vitro study shows Pfizer-BioNTech COVID-19 v…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced results from an in vitro study conducted by Pfizer and the University of Texas Medical Branch (UTMB...

Serum Institute of India obtains emergency use aut…

AstraZeneca's COVID-19 vaccine has been granted emergency use authorisation in India as well as Argentina, Dominican Republic, El Salvador, Mexico and Morocco for the act...

CureVac and Bayer join forces on COVID-19 vaccine …

Bayer has signed a collaboration and services agreement with CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines b...

New findings help explain how COVID-19 overpowers …

Seeking to understand why COVID-19 is able to suppress the body's immune response, new research from the USC Leonard Davis School of Gerontology suggests that mitochondri...

China grants conditional market approval for Sinop…

The inactivated COVID-19 vaccine developed by Beijing Institute of Biological Products of Sinopharm CNBG has been granted conditional registration by the NMPA of China, C...

Novavax announces initiation of PREVENT-19 pivotal…

Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced initiation of PREVEN...

AstraZeneca's COVID-19 vaccine authorised for emer…

AstraZeneca's COVID-19 vaccine has been approved for emergency supply in the UK, with the first doses being released today so that vaccinations may begin early in the New...

Pfizer and BioNTech to supply the European Union w…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced they will supply an additional 100 million doses of COMIRNATY®, the companies' COVID-19 Vaccine, to the 2...